The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 10, 2012
Filed:
Apr. 02, 2010
Trevor T. Charvat, San Jose, CA (US);
Cheng HU, Menlo Park, CA (US);
Anita Melikian, San Francisco, CA (US);
Aaron Novack, San Jose, CA (US);
Andrew M. K. Pennell, San Francisco, CA (US);
Sreenivas Punna, Sunnyvale, CA (US);
Edward J. Sullivan, San Jose, CA (US);
Xuefei Tan, Union City, CA (US);
William D. Thomas, San Jose, CA (US);
Solomon Ungashe, Fremont, CA (US);
Yibin Zeng, San Mateo, CA (US);
Trevor T. Charvat, San Jose, CA (US);
Cheng Hu, Menlo Park, CA (US);
Anita Melikian, San Francisco, CA (US);
Aaron Novack, San Jose, CA (US);
Andrew M. K. Pennell, San Francisco, CA (US);
Sreenivas Punna, Sunnyvale, CA (US);
Edward J. Sullivan, San Jose, CA (US);
Xuefei Tan, Union City, CA (US);
William D. Thomas, San Jose, CA (US);
Solomon Ungashe, Fremont, CA (US);
Yibin Zeng, San Mateo, CA (US);
ChemoCentryx, Inc., Mountain View, CA (US);
Abstract
Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.